Attached files

file filename
8-K - 8-K - MAGELLAN HEALTH INCa12-25208_18k.htm

Exhibit 99.1

 

GRAPHIC

NEWS RELEASE

 

Media Contact: David Carter, dwcarter@magellanhealth.com, (860) 507-1909
Investor Contact: Renie Shapiro, rshapiro@magellanhealth.com, (877) 645-6464

 

MAGELLAN HEALTH SERVICES REPORTS

THIRD QUARTER 2012 FINANCIAL RESULTS

 

-Updates 2012 Guidance-

 

AVON, Conn. — October 26, 2012 — Magellan Health Services Inc. (NASDAQ: MGLN) today reported financial results for the third quarter of 2012, as summarized below. For the quarter ended September 30, 2012, the company reported net revenue of $798.4 million, segment profit of $69.4 million, and net income of $66.3 million or $2.36 per diluted common share.  Segment profit represents income from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes.

 

Financial Results

 

 

 

Three Months Ended September 30

 

Nine Months Ended September 30

 

(Millions, except per share results)

 

2012

 

2011

 

Increase/
(Decrease)

 

2012

 

2011

 

Increase/
(Decrease)

 

Revenue

 

$

798.4

 

$

686.8

 

16.2

%

$

2,377.1

 

$

2,077.9

 

14.4

%

Segment Profit

 

69.4

 

55.5

 

25.0

%

189.6

 

207.2

 

(8.5

)%

Net Income

 

66.3

 

31.4

 

111.1

%

114.0

 

99.9

 

14.1

%

Earnings per Share

 

2.36

 

1.03

 

129.1

%

4.10

 

3.12

 

31.4

%

 

As of September 30, 2012, the company had unrestricted cash and investments of $277.4 million.

 

“Magellan had strong performance during the quarter and we are well positioned to complete the year,” said René Lerer, M.D., chairman and chief executive officer. “I think it is particularly significant that we have been able to drive improved clinical outcomes for the millions of individuals we serve, invest in our growth strategy, and produce these financial results despite a constantly changing health care environment.

 

“We are pleased with our recent contract award to administer the Military and Family Life Counseling (MFLC) program for the U.S. Department of Defense, which gives us a stronger foothold in the military and Federal government space.  We are also making important strides with our Medicaid strategy, which features our unique model of care and data analytic capabilities.  Whether it is expanding our reach into new markets like MFLC, or executing on our Medicaid strategy, Magellan is innovating in order to provide current and potential customers with new solutions.”

 

“Magellan’s strong financial results during the quarter reflect solid execution across all of our businesses,” said Jonathan N. Rubin, chief financial officer.  “We saw continued improvements in cost of care across all geographies in our Commercial Behavioral Health segment.  We have good momentum and strong cash flow, which gives us the opportunity to move forward with our plans to invest in our business for continued growth. I would note that our quarterly net income benefitted from the impact of a one-time reversal of tax contingencies, which increased EPS by approximately $1.24.”

 

Magellan Health Services—55 Nod Road, Avon CT 06001—www.MagellanHealth.com

 



 

Outlook

 

“Given these results, we are now expecting our full year segment profit to be at the upper end of the guidance range of $240 million to $260 million.  Primarily as a result of our lower effective tax rate, we are increasing our net income guidance to a range of $135 million to $155 million, and our diluted earnings per share guidance to a range of $4.83 to $5.55.  Our guidance does not assume the impact of any future share repurchases.

 

“Looking ahead, after adjusting the current 2012 guidance for approximately $15 million of favorable year-to-date out-of-period adjustments, we expect to see solid growth in segment profit in 2013.  This expectation is driven by several factors including the impact of new business and the impact of our care management initiatives, primarily in the Commercial behavioral health segment, which will be partially offset by contract terminations, increased investments in our Pharmacy and Medicaid strategic initiatives, and continued margin pressure resulting from economic strains on health plan and state clients.  We will provide detailed guidance during our December call.”

 

Earnings Results Conference Call

 

Management will host a conference call at 10:00 a.m. Eastern Time on Friday, October 26, 2012.  To participate in the conference call, interested parties should call 1-888-566-8408 and reference the passcode Third Quarter 2012 Earnings Call approximately 15 minutes before the start of the call.  The conference call will also be available via a live Webcast at Magellan’s investor relations page at www.MagellanHealth.com.

 

About Magellan Health Services:  Headquartered in Avon, Conn., Magellan Health Services Inc. is a leading specialty health care management organization with expertise in managing behavioral health, radiology and specialty pharmaceuticals, as well as public sector pharmacy benefits programs. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve.  As of September 30, 2012, Magellan’s customers include health plans, employers and government agencies, serving approximately 33.8 million members in our behavioral health business, 17.3 million members in our radiology benefits management segment, and 8 million members in our medical pharmacy management product.  In addition, the specialty pharmaceutical segment served 40 health plans and several pharmaceutical manufacturers and state Medicaid programs.  The company’s Medicaid Administration segment served 24 states and the District of Columbia.  For more information, visit www.MagellanHealth.com.

 

Cautionary Statement

 

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties.  All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2012 net income, segment profit, earnings per share, 2013 segment profit, and strategy. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year

 

2



 

ended December 31, 2011, filed with the Securities and Exchange Commission on February 28, 2012, and the company’s subsequent Quarterly Report on Form 10-Q expected to be filed with the Securities and Exchange Commission and posted on the company’s website later today.  Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure.  Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

 

# # #

 

3



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2011

 

2012 (1)

 

2011

 

2012 (1)

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

686,843

 

$

798,437

 

$

2,077,936

 

$

2,377,123

 

 

 

 

 

 

 

 

 

 

 

Cost and expenses:

 

 

 

 

 

 

 

 

 

Cost of care

 

448,051

 

516,238

 

1,323,197

 

1,543,361

 

Cost of goods sold

 

57,636

 

81,662

 

167,559

 

245,555

 

Direct service costs and other operating expenses (2)

 

130,038

 

135,574

 

393,384

 

412,496

 

Depreciation and amortization

 

15,069

 

15,239

 

43,288

 

45,172

 

Interest expense

 

457

 

537

 

1,422

 

1,713

 

Interest income

 

(592

)

(350

)

(2,265

)

(1,619

)

 

 

650,659

 

748,900

 

1,926,585

 

2,246,678

 

Income before income taxes

 

36,184

 

49,537

 

151,351

 

130,445

 

Provision (benefit) for income taxes

 

4,829

 

(16,725

)

51,467

 

16,420

 

Net income

 

31,355

 

66,262

 

99,884

 

114,025

 

Other comprehensive (loss) income (3)

 

(380

)

120

 

(302

)

208

 

Comprehensive income

 

$

30,975

 

$

66,382

 

$

99,582

 

$

114,233

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding — basic

 

29,900

 

27,521

 

31,406

 

27,346

 

Weighted average number of common shares outstanding — diluted

 

30,438

 

28,042

 

31,988

 

27,835

 

 

 

 

 

 

 

 

 

 

 

Net income per common share — basic

 

$

1.05

 

$

2.41

 

$

3.18

 

$

4.17

 

Net income per common share — diluted

 

$

1.03

 

$

2.36

 

$

3.12

 

$

4.10

 

 


(1)  For a more detailed discussion of Magellan’s results for the quarterly period ended September 30, 2012, refer to the Company’s Quarterly Report on Form 10-Q, which will be filed with the SEC on Friday, October 26, 2012, and the live broadcast or taped replay of the Company’s earnings conference call on Friday, October 26, 2012, which will be available at www.MagellanHealth.com.

 

(2)  Includes stock compensation expense of $4,425 and $4,468 for the three months ended September 30, 2011 and 2012, respectively, and $13,408 and $13,935 for the nine months ended September 30, 2011 and 2012, respectively.

 

(3)  Amounts are net of income tax provision (benefit) of $(238) and $78 for the three months ended September 30, 2011 and 2012, respectively, and $(189) and $134 for the nine months ended September 30, 2011 and 2012, respectively.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

 

Nine Months Ended September 30,

 

 

 

2011

 

2012 (1)

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

99,884

 

$

114,025

 

 

 

 

 

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

43,288

 

45,172

 

Non-cash interest expense

 

320

 

544

 

Non-cash stock compensation expense

 

13,408

 

13,935

 

Non-cash income tax expense

 

7,259

 

12,395

 

Non-cash amortization on investments

 

9,660

 

5,373

 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

 

 

 

 

 

Restricted cash (2) 

 

(38,825

)

(59,777

)

Accounts receivable, net

 

(8,439

)

604

 

Pharmaceutical inventory

 

(3,697

)

(2,002

)

Other assets

 

2,680

 

(4,218

)

Accounts payable and accrued liabilities

 

(10,216

)

(17,854

)

Medical claims payable and other medical liabilities

 

(15,463

)

37,422

 

Tax contingencies

 

(7,241

)

(34,616

)

Other

 

3,501

 

654

 

Net cash provided by operating activities

 

96,119

 

111,657

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Capital expenditures

 

(38,468

)

(53,049

)

Acquisitions and investments in businesses, net of cash acquired

 

(376

)

 

Purchase of investments

 

(210,890

)

(197,525

)

Maturity of investments

 

231,093

 

215,150

 

Net cash used in investing activities

 

(18,641

)

(35,424

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments to acquire treasury stock

 

(327,886

)

 

Proceeds from issuance of equity

 

20,000

 

 

Proceeds from exercise of stock options and warrants

 

34,755

 

13,092

 

Other

 

839

 

135

 

Net cash (used in) provided by financing activities

 

(272,292

)

13,227

 

 

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

 

(194,814

)

89,460

 

Cash and cash equivalents at beginning of period

 

337,179

 

119,862

 

Cash and cash equivalents at end of period

 

$

142,365

 

$

209,322

 

 


(1)  The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012 will be filed with the SEC on October 26, 2012.

 

(2)  Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change.  During the nine months ended September 30, 2011 and 2012, restricted investments of $45,749 and $27,421, respectively, were shifted to restricted cash that resulted in an operating cash flow use.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT

(Unaudited)

(In thousands)

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2011

 

2012 (1)

 

2011

 

2012 (1)

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

 

 

 

 

 

 

 

 

- Commercial

 

$

135,365

 

$

176,713

 

$

425,086

 

$

535,464

 

- Public Sector

 

362,104

 

407,265

 

1,074,904

 

1,206,289

 

- Radiology Benefits Management

 

78,659

 

88,126

 

258,479

 

253,809

 

- Specialty Pharmaceutical Management

 

73,792

 

101,503

 

213,388

 

303,677

 

- Medicaid Administration (2) 

 

57,692

 

40,263

 

167,622

 

131,143

 

- Elimination (2) 

 

(20,769

)

(15,433

)

(61,543

)

(53,259

)

Total net revenue

 

686,843

 

798,437

 

2,077,936

 

2,377,123

 

 

 

 

 

 

 

 

 

 

 

Cost of care

 

 

 

 

 

 

 

 

 

- Commercial

 

81,503

 

100,973

 

235,938

 

323,992

 

- Public Sector (2) 

 

318,807

 

358,959

 

933,662

 

1,058,384

 

- Radiology Benefits Management

 

49,186

 

58,080

 

157,731

 

166,364

 

- Medicaid Administration

 

19,324

 

13,659

 

57,409

 

47,880

 

- Elimination (2) 

 

(20,769

)

(15,433

)

(61,543

)

(53,259

)

Total cost of care

 

448,051

 

516,238

 

1,323,197

 

1,543,361

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold - Specialty Pharmaceutical Management

 

57,636

 

81,662

 

167,559

 

245,555

 

 

 

 

 

 

 

 

 

 

 

Direct service costs and other operating expenses

 

 

 

 

 

 

 

 

 

- Commercial

 

36,582

 

43,007

 

113,502

 

127,825

 

- Public Sector

 

16,741

 

22,948

 

50,203

 

66,850

 

- Radiology Benefits Management

 

14,717

 

14,045

 

47,280

 

41,113

 

- Specialty Pharmaceutical Management

 

6,563

 

7,071

 

18,658

 

19,744

 

- Medicaid Administration

 

26,221

 

20,494

 

78,056

 

63,788

 

- Corporate

 

29,214

 

28,009

 

85,685

 

93,176

 

Total direct service costs and other operating expenses

 

130,038

 

135,574

 

393,384

 

412,496

 

 

 

 

 

 

 

 

 

 

 

Stock compensation expense (3)

 

 

 

 

 

 

 

 

 

- Commercial

 

(208

)

(293

)

(677

)

(830

)

- Public Sector

 

(218

)

(278

)

(654

)

(835

)

- Radiology Benefits Management

 

(355

)

(419

)

(1,238

)

(1,179

)

- Specialty Pharmaceutical Management

 

(380

)

(121

)

(639

)

(445

)

- Medicaid Administration

 

(36

)

(117

)

(100

)

(259

)

- Corporate

 

(3,228

)

(3,240

)

(10,100

)

(10,387

)

Total stock compensation expense

 

(4,425

)

(4,468

)

(13,408

)

(13,935

)

 

 

 

 

 

 

 

 

 

 

Segment profit (loss)

 

 

 

 

 

 

 

 

 

- Commercial

 

17,488

 

33,026

 

76,323

 

84,477

 

- Public Sector

 

26,774

 

25,636

 

91,693

 

81,890

 

- Radiology Benefits Management

 

15,111

 

16,420

 

54,706

 

47,511

 

- Specialty Pharmaceutical Management

 

9,973

 

12,891

 

27,810

 

38,823

 

- Medicaid Administration

 

12,183

 

6,227

 

32,257

 

19,734

 

- Corporate and Elimination

 

(25,986

)

(24,769

)

(75,585

)

(82,789

)

Total segment profit

 

$

55,543

 

$

69,431

 

$

207,204

 

$

189,646

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of segment profit to income before income taxes:

 

 

 

 

 

 

 

 

 

Segment profit

 

$

55,543

 

$

69,431

 

$

207,204

 

$

189,646

 

Stock compensation expense

 

(4,425

)

(4,468

)

(13,408

)

(13,935

)

Depreciation and amortization

 

(15,069

)

(15,239

)

(43,288

)

(45,172

)

Interest expense

 

(457

)

(537

)

(1,422

)

(1,713

)

Interest income

 

592

 

350

 

2,265

 

1,619

 

Income before income taxes

 

$

36,184

 

$

49,537

 

$

151,351

 

$

130,445

 

 


(1)  The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012 will be filed with the SEC on October 26, 2012.

 

(2)  Public Sector has subcontracted with Medicaid Administration to provide pharmacy benefits management services on a limited risk basis for one of Public Sector’s customers.  As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3)  Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.